MedTrace Logo

R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)

NCT01427114 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2021-05-06

No results posted yet for this study

Summary

The purpose of this study is to determine how efficient the combination of rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) is in the treatment of stage I or II non-conjunctival ocular adnexal MALT lymphoma (OAML).

Conditions

Interventions

DRUG

rituximab, cyclophosphamide, vincristine, and prednisolone

6 cycles of R-CVP followed by 2 cycles of rituximab

Sponsors & Collaborators

  • Seoul St. Mary's Hospital

    collaborator OTHER

  • Konkuk University Medical Center

    lead OTHER

Principal Investigators

  • Seok-Goo Cho, Ph.D. · Seoul St. Mary's Hospital

  • Sung-Yong Kim, Ph.D. · Konkuk University Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-01
Primary Completion
2014-08-01
Completion
2021-01-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01427114 on ClinicalTrials.gov